Sunday, December 14, 2025
7.1 C
London

Tag: Starpharma

Starpharma: Receives $7.1m R&D tax incentive refund

Starpharma Receives $7.1m R&D tax incentive refund Biopharmaceutical company Starpharma (SPL) receives a $7.1 million research and development tax...

Starpharma: Registers VIRALEZE nasal spray in Indonesia

Starpharma Registers VIRALEZE nasal spray in Indonesia Starpharma (SPL) registers its nasal spray product VIRALEZE in Indonesia after gaining...

Starpharma: Spends September quarter progressing DEP technology

Starpharma Spends September quarter progressing DEP technology Starpharma (SPL) spent the September quarter progressing its DEP technology and signing...

Starpharma: Expands research program with Genentech

Starpharma Expands research program with Genentech Starpharma (SPL) expands its research agreement with Genentech for its drug delivery technology,...

Starpharma: Receives $7.7m R&D tax refund

Starpharma Receives $7.7m R&D tax refund Starpharma (SPL) receives a $7.7 million research and development tax incentive refund The...

Starpharma: Continues VIRALEZE success in December quarter

Starpharma Continues VIRALEZE success in December quarter Starpharma (SPL) releases its September quarterly report, with the period again highlighted...

Starpharma: Advances progress for COVID-19 nasal spray

During the September quarter, Starpharma (SPL) achieved several milestones with its SPL7013 COVID-19 nasal spray Additionally, the pharmaceutical...

Starpharma: Raises $45M for next phase of growth

Pharmaceutical company Starpharma (SPL) has raised $45 million via an oversubscribed share placement All up, 30 million new...

Starpharma: Receives $1M MRFF funding for COVID-19 nasal spray

Starpharma (SPL) has been awarded $1M in matched funding by the Australian Government's Medical Research Future Fund (MRFF) ...

Starpharma: Updates market on nasal spray

Starpharma has provided updates on its COVID-19 nasal protection spray, which uses antiviral dendrimer SPL7013 Already the company...